

Award Number: W81XWH-07-1-0362

TITLE: Notch as a Diagnostic Marker and Therapeutic Target in
Human Breast Cancer

PRINCIPAL INVESTIGATOR: Jan K. Kitajewski, Ph.D.

CONTRACTING ORGANIZATION: Columbia University Medical Center
New York, NY 10032

REPORT DATE: May 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

☒ Approved for public release; distribution unlimited

☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 22-05-2008		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 23 APR 2007 - 22 APR 2008	
4. TITLE AND SUBTITLE Notch as a Diagnostic Marker and Therapeutic Target in Human Breast Cancer				5a. CONTRACT NUMBER W81XWH-07-1-0362	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jan K. Kitajewski, Ph.D. Email: jkk9@columbia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research Materiel Command * Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT X Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We hypothesize that Notch and Jagged-1 expression on breast cancer cells, as well as Delta like-4 on breast tumor vessels, present a diagnostic and therapeutic target for detection and treatment of this devastating disease. Our combined objective is to utilize mouse models to establish whether 1) human breast cancer cells that express Jagged-1 and tumor vessels that express Delta-4, respectively can be detected using a novel diagnostic platform, 2) tumor derived proteins that shed upon Notch activation can be detected in serum of tumor bearing animals, and 3) blockade of Notch pathway activation, using neutralizing antibodies and a decoy receptor, will mitigate the growth of breast tumor in animals. The ultimate goal of these studies is to utilize the expertise of Drs. Diacovo and Kitajewski to validate Notch as a diagnostic and therapeutic target in breast cancer in order to develop paradigms that can be used in the clinic to detect and treat breast cancer.					
15. SUBJECT TERMS Notch, Jagged1, Breast Cancer, Angiogenesis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unlimited	18. NUMBER OF PAGES 21	19a. NAME OF RESPONSIBLE PERSON Jan K. Kitajewski
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (+ area code) 212-851-4688

TABLE OF CONTENTS

Introduction.....	4
Body.....	5-10
Key Research Accomplishments.....	11
Reportable Outcomes.....	11
Conclusions.....	11
References.....	12
Appendices.....	13-21

INTRODUCTION

This proposal focuses on Notch signaling in breast cancer and asks whether Notch and Notch ligands represent diagnostic markers of and therapeutic targets for breast cancer.

The Notch family and Ligands. In the context of cancer biology, Notch signaling has been proposed to promote tumor-induced angiogenesis, and tumorigenesis by blocking cell differentiation. Notch is a transmembrane receptor that interacts with ligands expressed on the surface of cells. In mammals, there are four Notch genes (1-4) and five ligands, referred to as Jagged (Jagged-1 and Jagged-2) or Deltas (1-3) (also called Delta-like). Many of the Notch proteins are widely expressed with the exception of Delta-4, which appears to be highly expressed on tumor endothelium as described below. Moreover, both Notch1 and Jagged-1 are preferentially expressed on breast cancer cells [1]. Based on these observations, this proposal will focus on the receptor, *Notch1*, and the ligands, *Delta-4* and *Jagged-1*, in developing new diagnostic strategies and therapies in the war against breast cancer. Of key importance to the diagnostic part of this proposal is an understanding that during Notch signal activation there is release of the extracellular domains of Notch1, Delta-4 and Jagged-1. The shed products are schematized in Figure 1B, consisting of cleavage products, soluble Jagged-1 (sJagged-1), soluble Delta-4 (sDelta-4), and Notch1 ectodomain (Notch1 ECD).

Delta-4 as a Tumor Endothelial Marker.

The growth and metastasis of breast cancer relies on the formation of new blood vessels by the process of angiogenesis. Angiogenesis involves the sprouting of new vessels from pre-existing normal vasculature, with the migration of these vessels into the tumor [2]. Recent clinical trials with the anti-angiogenic agent Avastin (a function blocking antibody to VEGF) validate this concept in women with breast cancer where survival is enhanced [3-5]. Interestingly, evidence is mounting that blockade of VEGF activity may be overcome through Notch signal activation in tumor endothelium (our unpublished observations), suggesting that inhibition of both pathways may be advantageous in the treatment of breast cancer [6]. In addition, Delta-4 (a Notch ligand) has a provocative expression pattern in breast cancer as it is highly expressed on human breast tumor vessels [7]. Thus, Delta-4 is a true tumor endothelial cell marker that may be exploited for diagnosis and targeted therapies as outlined in this proposal.

Notch1 and Jagged-1 are over-expressed in human breast cancers. Notch signaling may be activated in greater than 50% of human breast cancers, implicating its role in tumor development [8, 9]. Moreover, expression of Notch1 and its ligand Jagged-1 on breast tumor cells has been shown to correlate with poor prognosis in terms of survival [1].

Specific Aims

1. Diagnostic Imaging of Jagged-1/Delta-4 Expressing Breast Tumors.

Utilize a nanoparticle based imaging platform (Diacovo) to detect for the elevated expression of the Notch ligands (Dll4) in animals bearing murine or xenografted human breast tumors (Kitajewski).

2. Detection of Jagged-1 ectodomain shedding from Breast Tumors.

Determine if the extracellular domain of Delta-4 and Jagged-1 are shed into serum in tumor bearing mice (Kitajewski). Generate antibodies to detect human forms of these proteins (Diacovo) for development of an ELISA based detection system (Kitajewski).

3. Inhibition of Breast Tumors with Notch Neutralizing Agents and Notch decoys.

Explore the consequences of therapeutic intervention of Notch signaling in breast tumor models with either Notch decoy (Kitajewski) or neutralizing antibodies (Diacovo).

Body

Specific Aims 1: Diagnostic Imaging of Jagged-1/Delta-4 Expressing Breast Tumors.

Goal: Utilize a nanoparticle based imaging platform (Diacovo) to detect for the elevated expression of the Notch ligands (JAGGED1 and DLL4) in whole animals bearing murine or xenografted human breast tumors (Kitajewski).

We have made progress and report here on **Task2: Development of Hybridoma lines producing monoclonal antibodies against Jagged-1 (Year 1) and Delta-4 (Year 2)**

Update for JAGGED1 antibody generation:

Expression construct to present human JAGGED1 as a human antigen on pre-B cells. The full-length human JAGGED-1 (JAG1) cDNA was cloned from cDNA generated from human umbilical venous endothelial cells (HUVEC). The cDNA was sequenced and then used to generate several expression vectors. First, full-length human JAG1 was fused in frame with GFP this JAG1–GFP fusion protein was introduced into the pre-B cell line L1-2. Both Western Blot analysis and FACS analysis confirmed expression and these cells will be introduced into syngeneic mice in order to elicit an antibody response to the extracellular domain of human JAGGED1.

Generation of expression vector and CHO cells expressing extracellular domain of human JAGGED1. We generated a construct fusing the extracellular part of human JAG1 with the FLAG tag, generating a cDNA that would encode a secreted form containing the extracellular domain of JAG1. The soluble JAG1-ECD-FLAG was expressed in Chinese Hamster ovary K1 (CHO-K1) cells and then CHO clones were screened for their ability to express high levels of secreted JAG1-Flag.

hJAG1-ECD purification: A CHO-K1 cell clone with stable-expression hJAG1-ECD-Flag has been selected. The expression and secretion of hJAG1-ECD-Flag has been verified by western-blot using anti-Flag antibodies (data not shown). Conditioned serum-free medium was collected from CHO-K1-hJAG1-ECD-Flag (clone14) grown in culture.

The purification strategy to obtain hJAG1-ECD-Flag is as follows:

- 1) pre-purification with Q-sepharose Ion Exchange column. After column loading and washing, bound proteins are eluted with manual pre-mixed NaCl gradient buffer. Samples from all fractions are subject for SDS-PAGE gel analysis with Coomassie-blue and M2-antibody western-blot (Figure 1). The identity of hJAG1-ECD is also confirmed with AF1277 Goat-anti-JAG1 antibody (data not shown).
- 2) Positive fractions from Q column further purified with M2-antibody Affinity column that specifically binds protein with Flag- tag. The elution is done by 0.1M Glycine (pH 3.5, with neutralizing buffer in the collection tube). Samples from all fractions are subject for SDS-PAGE gel analysis with Coomassie-blue staining (Figure 2)

The purified JAG1-ECD-Flag protein was dialyzed against phosphate buffered saline (PBS) and concentrated using a Centricon 30K. The final concentration was determined by BCA Protein Assay (Pierce) and the yield was approximately 3 mg; an abundant amount to be used as an antigen for antibody production.

Figure 1. Western blot analysis of hJAG1-ECD purification using Q-Sepharose.





Figure 2. Western blot of hJAG1-ECD purification using Flag affinity chromatography.



hJAG1-ECD hybridoma production: Mice have been purchased and the initial injections will commence.

Update for the DLL4 antibody generation:

Expression construct to present human DELTA-LIKE 4 (DLL4) as a human antigen on pre-B cells.
The full-length human DELTA-LIKE 4 (DLL4) cDNA was cloned from cDNA generated from HUVEC. The cDNA was sequenced and then used to generate several expression vectors. First, full-length human DLL4 was fused in frame with GFP this DLL4–GFP fusion protein was introduced into the pre-B cell line L1-2. Both Western Blot analysis and immunofluorescence analysis confirmed expression (Figure 3). These B cells expressing DLL4-GFP will eventually be used to introduce into syngeneic mice in order to elicit an antibody response to the extracellular domain of human DLL4.

Figure 3.
Western blot (a) and Immunofluorescence (b) analysis of Bcell/L1-2/DLL4-GFP protein expression




Figure legend:

Full length human DLL4 with GFP- and flag-tag at C-terminal expression in 293T cells.
A) Western-blot using M2 (anti-Flag) antibody. Full length hDLL4-GFP-Flag is about 105 kDa. GFP-Flag is about 28 kDa, while there is a splicing form of GFP-Flag starting from Met80 within GFP sequence and the size is about 18.7 kDa.
B) Human full length DLL4-GFP-Flag is expressed mainly on cell membrane (as shown in figure b insert).

Generation of expression vector and CHO cells expressing extracellular domain of human DLL4.

We generated a construct fusing the extracellular part of human DLL4 with the FLAG tag, generating a cDNA that would encode a secreted form containing the extracellular domain of JAG1. The soluble JAG1-ECD-FLAG was expressed in Chinese hamster ovary K1 (CHO-K1) cells and then CHO clones were screened for their ability to express high levels of secreted JAG1-Flag.


Specific Aims 2: **Detection of Jagged-1 ectodomain shedding from Breast Tumors.**

Determine if the extracellular domain of Delta-4 and Jagged-1 are shed into serum in tumor bearing mice (Kitajewski). Generate antibodies to detect human forms of these proteins (Diacovo) for development of an ELISA based detection system (Kitajewski).

We have made progress and report here on **Task5**. Screen tumor xenografts for shed Jagged-1 or Delta-4 in serum of tumor xenografts. (Months 8-24)

We began a pilot study to determine how readily we can detect secreted Notch ligands and Notch antagonists in murine serum. Injection of an adenovirus into the eye vein was done with Ad encoding either Fc or N1ECDFc into immunocompromised mice. Eight immunocompromised mice for each were injected with 2.5×10^9 Ad-N1ECDFc and six with Ad-Fc. Serum collected from the mice was used in Western blot analysis and we were able to detect N1ECDFc within the serum by immunoblotting (Figure 4). Thus, we can compare these levels to that shed by tumors, as described in Task 5. This system will also serve as a positive control for the ELISA assay development. We have already generated an adenovirus expressing the JAG1-ECD-Flag protein, described above, and will use this also as a positive control for the detection of shed JAGGED1.

Figure 4. Detection of N1ECDFc in serum of mice injected with adenovirus.



Specific Aims 3:

Inhibition of Breast Tumors with Notch Neutralizing Agents and Notch decoys.

Explore the consequences of therapeutic intervention of Notch signaling in breast tumor models with either Notch decoy (Kitajewski) or neutralizing antibodies (Diacovo).

We have made progress and report here on **Task 4:** Use Neutralizing Antibodies and Notch1 antagonist to block Jagged-1 driven mammary tumors.

Introduction to Notch decoy: Notch1ECDFc. We have generated Notch antagonists that are composed of the signal peptide and EGF-like repeats of Notch1 fused in frame with Fc fragment of human IgG. Using an *in vitro* co-culture assay, we have found that the Notch antagonists N1ECDFc perturb ligand-activated signaling of Notch1, Notch2 and Notch4 (data not shown). Thus, we proposed to generate mammary tumor cell lines expressing these Notch antagonists and transplant them into immunocompromised mice. The research on Notch1ECDFc has led to a reportable outcome; that is a published paper on the effect of Notch1ECDFc on mouse mammary tumor growth and angiogenesis. Please see Appendix paper; Funahashi *et al.*, "A Notch1 ectodomain construct inhibits endothelial Notch signaling, tumor growth, and angiogenesis" **Cancer Research** 68:4727-35. The work most relevant to the annual report is briefly described here.

N1ECDFc suppresses angiogenesis in a mouse model of breast cancer. We determined the affect of expressing the Notch antagonist, N1ECDFc on the tumorigenicity of mammary tumor cells. FGF-expressing Mm5MT cells were retrovirally infected with empty virus, Fc (control) or N1ECDFc expressing viruses and cell populations generated by hygromycin selection. In soft agar assays, expression of the Notch antagonists had a nominal affect on soft agar growth as determined by WST-We evaluated our Notch antagonist, N1ECDFc, in a mouse model of breast cancer to determine its effects on tumor growth and angiogenesis. In this tumor model, FGF4-expressing Mm5MT (FGF4-Mm5MT) are tumorigenic when subcutaneously implanted in syngeneic mice (data not show). In this tumor model, angiogenesis is promoted by hypoxia-driven VEGF-A expression. We infected FGF4-Mm5MT with empty vector lentivirus, or lentiviruses encoding either human Fc or N1ECDFc. Tumor lines were implanted subcutaneously and allowed to grow for 21 days. Two independent trials were monitored for tumor growth for 3 weeks (Figure 5). In the two trials, expression of N1ECDFc significantly inhibited tumor growth.





Figure 5 Notch decoy inhibits tumor growth of Mm5MT-FGF4 in syngeneic C3H mice. Tumor volume over 21 days post-inoculation of Mock, Fc and N1ECDFc expressing mammary tumor cells. **A)** Average of two independent experiments. **B)** Third independent experiment.

N1ECDFc expressed in liver via adenovirus vector affects mammary tumor growth and angiogenesis.

We have begun an alternate approach in expressing the Notch antagonists in the murine Mm5MT tumor model. We chose to tail vein inject an adenovirus encoding either GFP or N1ECDFc into immunocompromised mice. Five immunocompromised mice for each were injected with 2.5×10^9 Ad-GFP or Ad-N1ECDFc, or 1.25×10^9 Ad-N1ECDFc. The following day 1×10^6 tumor cells were subcutaneously injected. After 20 days, a 30% suppression of tumor growth was observed in the mice that were injected with Ad-N1ECDFc (Figure 6). This inhibition was also evident when animals were sacrificed at 27 days. The livers of the Ad-GFP injected mice expressed GFP demonstrating that the adenoviral infection of the liver was successful (data not shown). We also collected serum from the mice were able to detect N1ECDFc within the serum by immunoblotting (data not shown). Thus, we believe that circulating N1ECDFc suppressed tumor growth. This represents a model we will use to compare and contrast Notch1ECDFc activity against Jagged1 neutralizing agents (antibody).

Figure 6. Tail vein injection of Ad-N1ECDFc suppresses growth of xenografted mammary tumors (Mm5MT)



KEY RESEARCH ACCOMPLISHMENTS

- Cloned the human JAGGED1 and DLL4 cDNAs, sequenced constructs and generated expression clones to be used to purify antigen.
- Generated CHO cells producing secreted Jagged1 ECD and purified 3 milligrams of Jagged1 Extracellular domain (ECD) to be used as antigen for hybridoma production.
- Generated B-cell line expressing either GFP tagged Jagged1 or DLL4.
- Initiated Hybridoma production for Jagged1
- Found that the expression of Notch antagonists altered the growth of murine mammary tumor xenografts.
- Developed a system to generate circulating Notch antagonists in mice using tail vein injects of adenovirus.
- Demonstrated that circulating Notch antagonist inhibited tumor growth of subcutaneous xenografts in immunocompromised mice.

REPORTABLE OUTCOMES (PUBLICATIONS/ABSTRACTS)

Publications:

Funahashi Y, Hernandez S, Das I, Ahn A, Huang J, Vorontchinkhina M, Sharma A, Kanamaru E, Borisenko V, DeSilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ, **Kitajewski J.** (2008) A Notch1 ectodomain construct inhibits endothelial Notch signaling, tumor growth and angiogenesis. *Cancer Research*, **68**: 4727-35*.

Dufraine J, Funahashi Y, **Kitajewski J.** (2008). Notch signaling regulates tumor angiogenesis by diverse mechanisms. *Oncogene*, **27**: 5132-7.

CONCLUSIONS

The proposal **objective** is to explore the importance of Jagged1 and Dll4 in mammary tumor growth and to determine the diagnostic potential of assessing Jagged1 or Dll4 levels in tumors or as shed proteins in serum. Much of our efforts has gone toward developing hybridoma antibodies against human JAGGED1 and DLL4 extracellular domains. To this end we have generated full length cDNA clones of JAGGED1 and DLL4, sequenced these cDNAs and then generated a variety of expression constructs to be used in hybridoma production. In the case of JAGGED1, we have generated CHO cells secreting a FLAG tagged extracellular domain of JAGGED1 and purified substantial amounts of protein to be used as antigen. In the case of DLL4 we have generated CHO cells expressing DLL4 and a B-cell line that may be used as a source of antigen. We have also demonstrated that we can detect Notch proteins in the serum of mice expressing these via adenovirus vectors and we propose to use this system as a positive control for the development of ELISA assays to detect shed JAGGED1 or DLL4 proteins. In addition, we have developed a system that uses injection of Notch antagonist expressing adenoviruses into immunocompromised mice that allow for studies assessing the effect of Notch antagonists in nude mice with tumor xenografts. This leads to expression of the antagonist in the circulation and inhibition of mouse mammary tumor xenografts. We found that Notch decoy blocked tumor growth, presumably by blocking tumor angiogenesis.

REFERENCES

1. Reedijk, M., et al., *High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival*. Cancer Res, 2005. **65**(18): p. 8530-7.
2. Carmeliet, P. and R.K. Jain, *Angiogenesis in cancer and other diseases*. Nature, 2000a. **407**(6801): p. 249-257.
3. Miller, K.D., et al., *Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer*. J Clin Oncol, 2005. **23**(4): p. 792-9.
4. Hampton, T., *Monoclonal antibody therapies shine in breast cancer clinical trials*. Jama, 2005. **293**(24): p. 2985-9.
5. Miller, K.D., *Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?* Breast Cancer Res, 2004. **6**(3): p. 128-32.
6. Li, J.L. and A.L. Harris, *Notch signaling from tumor cells: a new mechanism of angiogenesis*. Cancer Cell, 2005. **8**(1): p. 1-3.
7. Mailhos, C., et al., *Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis*. Differentiation, 2001. **69**(2-3): p. 135-44.
8. Pece, S., et al., *Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis*. J Cell Biol, 2004. **167**(2): p. 215-21.
9. Stylianou, S., R.B. Clarke, and K. Brennan, *Aberrant activation of notch signaling in human breast cancer*. Cancer Res, 2006. **66**(3): p. 1517-25.

A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis

Yasuhiro Funahashi,¹ Sonia L. Hernandez,^{3,4} Indranil Das,¹ Audrey Ahn,¹ Jianzhong Huang,^{4,5} Marina Vorontchikhina,¹ Anshula Sharma,¹ Emi Kanamaru,¹ Valeriya Borisenko,¹ Dinuka M. DeSilva,¹ Akihiko Suzuki,⁷ Xing Wang,¹ Carrie J. Shawber,¹ Jessica J. Kandel,^{4,5,6} Darrell J. Yamashiro,^{2,4,6} and Jan Kitajewski^{1,2,6}

Departments of ¹Obstetrics and Gynaecology, ²Pathology, ³Nutrition, ⁴Pediatrics, and ⁵Surgery, ⁶Institute of Cancer Genetics, Columbia University Medical Center, New York, New York; and ⁷Tohoku University Medical Center, Sendai, Japan

Abstract

Notch signaling is required for vascular development and tumor angiogenesis. Although inhibition of the Notch ligand Delta-like 4 can restrict tumor growth and disrupt neo-vasculature, the effect of inhibiting Notch receptor function on angiogenesis has yet to be defined. In this study, we generated a soluble form of the Notch1 receptor (Notch1 decoy) and assessed its effect on angiogenesis *in vitro* and *in vivo*. Notch1 decoy expression reduced signaling stimulated by the binding of three distinct Notch ligands to Notch1 and inhibited morphogenesis of endothelial cells overexpressing Notch4. Thus, Notch1 decoy functioned as an antagonist of ligand-dependent Notch signaling. In mice, Notch1 decoy also inhibited vascular endothelial growth factor-induced angiogenesis in skin, establishing a role for Notch receptor function in this process. We tested the effects of Notch1 decoy on tumor angiogenesis using two models: mouse mammary Mm5MT cells overexpressing fibroblast growth factor 4 (Mm5MT-FGF4) and NGP human neuroblastoma cells. Exogenously expressed FGF4 induced Notch ligand expression in Mm5MT cells and xenografts. Notch1 decoy expression did not affect tumorigenicity of Mm5MT-FGF4 cells *in vitro* but restricted Mm5MT-FGF4 xenograft growth in mice while markedly impairing neoangiogenesis. Similarly, Notch1 decoy expression did not affect NGP cells *in vitro* but disrupted vessels and decreased tumor viability *in vivo*. These results strongly suggest that Notch receptor signaling is required for tumor neoangiogenesis and provides a new target for tumor therapy. [Cancer Res 2008;68(12):1-9]

Introduction

Angiogenesis is exquisitely regulated by multiple signal pathways, including vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), and hepatocyte growth factor (HGF). Among these, VEGF critically influences almost all steps of angiogenesis, including endothelial proliferation, survival, and tube formation (1). Consistent with this protean role, VEGF inhibitors reduce angiogenesis in preclinical models and have been clinically validated as cancer therapy (2). Despite this established efficacy,

different tumor types exhibit widely varying susceptibility to VEGF blockade (2). The underlying reasons for this variability are not clear. One possibility is that alternative signals rescue tumor vasculature, allowing for perfusion despite VEGF inhibition. Identification of such pathways is therefore of clear therapeutic importance.

The highly conserved Notch gene family encodes transmembrane receptors (Notch1, Notch2, Notch3, Notch4) and ligands [Jagged1, Jagged2, Delta-like 1 (Dll1), Dll3, Dll4], also transmembrane proteins. Upon ligand binding, the Notch cytoplasmic domain (NotchIC) is released by presenilin/ γ -secretase (3). Notch signaling defects produce severe vascular defects in embryos (4), with haploinsufficiency of Dll4 causing lethality. The potential role of Notch signaling in tumor angiogenesis has thus excited much recent interest. Mice transgenic for a Dll4 reporter construct show expression in tumor endothelial cells (EC; ref. 5) and increased Dll4 expression has been detected in human cancers (6, 7). Two recent reports confirm that Dll4 plays a critical role in neoplastic endothelium, as Dll4 blockade suppresses growth and perfusion in experimental tumors (8, 9). Intriguingly, in these studies Dll4 inhibition disorganized tumor vasculature rather than simply preventing vessel proliferation, suggesting that Dll4 is required for the assembly of functional vessels.

Recent data indicate that Notch receptors also play a role in tumor angiogenesis. For example, in head and neck squamous cell carcinoma (HNSCC), HGF was shown to up-regulate expression of Jagged1 on tumor cells, but not on endothelium. Increased Jagged1 expression activated Notch signaling in neighboring ECs, stimulating tumor angiogenesis and growth in mice (10). Thus, these data suggest that there are at least two distinct mechanisms for activating Notch signaling in tumor endothelium.

Accumulating evidence shows the intricate linkage of Notch activation and VEGF signaling. VEGF can induce the expression of Notch receptors and Dll4 (11), with Dll4 reducing expression of VEGF receptor 2 (VEGFR2) in ECs, contributing to feedback regulation of VEGF (12). More recently, Notch receptors have been shown to regulate the expression of endothelial VEGFRs (13). These studies suggest that VEGF-mediated and Notch-mediated signal pathways cross-regulate one another by mechanisms yet to be fully understood.

In these experiments, we evaluated the role of Notch receptor activation in angiogenesis using a novel soluble construct based on the extracellular domain of Notch1 (Notch1 decoy). *In vitro*, Notch1 decoy inhibited both ligand-induced activation of Notch signaling and morphogenesis of ECs adenovirally overexpressing Notch4. *In vivo*, Notch1 decoy reduced VEGF-stimulated angiogenesis in murine skin. Notch1 decoy expression delayed growth of murine Mm5MT xenografts in which Jagged1 expression was up-regulated

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

J.J. Kandel and D.J. Yamashiro contributed equally to this manuscript.

Requests for reprints: Jan Kitajewski, 1130 Street Nicholas Avenue, Irving Cancer Research Center, New York, NY 10032. Phone: 212-851-4688; Fax: 212-851-4690; E-mail: jkk9@columbia.edu.

©2008 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-07-6499




Figure 1. Notch1 decoy inhibits activation of Notch signaling stimulated by Notch ligands. *A*, schematic of Notch1 decoy containing the 36 endothelial growth factor repeats of rat Notch1 fused to human Fc. *B*, Western blotting to detect secreted Notch1 decoy in conditioned medium from HUVECs transduced with Ad-Notch1 decoy at indicated m.o.i. Bar, 100 μ m. *C*, Notch1 decoy inhibits ligand-induced CSL reporter activity in coculture signaling assay. Activation of Notch signaling was measured in HeLa cells expressing Notch1 cocultured with 293 cells expressing Notch ligands. Columns, mean; bars, SD. *, $P < 0.05$.

by ectopic expression of FGF4 and disrupted vasculature and tumor viability in NGP neuroblastoma tumors. Taken together, these data support a requirement for Notch receptor function during neoangiogenesis, including VEGF-induced angiogenesis, and suggest that inhibition of this pathway may provide an effective new antitumor strategy.

Materials and Methods

Reagents and expression vectors. Compound E was purchased from Calbiochem, and PD166866 (14) was from Eisai. Notch1 decoy encodes the rat Notch1 ectodomain (bp 241-4229, accession no. X57405) fused in frame to human IgG Fc. Retroviral pHyTC-Jagged1, pHyTC-Dll1, pHyTC-Dll4, and pBos-Notch1 have been described (15). Notch1 decoy and Fc were engineered into retroviral vector pHyTCX, and mouse FGF4 engineered into pQNCX. Adenoviral constructs encoding LacZ and mouse Notch4 and pAdlox-GFP have been described (16, 17).

Human umbilical vascular ECs, adenoviral, and retroviral infections. Human umbilical vascular ECs (HUVEC) were isolated as described (18), and mouse mammary carcinoma Mm5MT was obtained (American Type Culture Collection). We used adenovirus (Ad) at indicated multiplicity of infection (m.o.i.) and retroviral supernatants from GP2-293 cells (BD Biosciences) for infection. HUVECs were selected using 300 μ g/mL hygromycinB (Invitrogen), and Mm5MT transfectants expressing FGF4 (Mm5MT-FGF4) was selected in 1 mg/mL G418 (Life Technologies-Invitrogen) with double transfectants in 300 μ g/mL hygromycinB. Both Mm5MT-FGF4-Notch1 decoy and NGP-Notch1 decoy lines expressed

Notch1 decoy, with protein detected in both cell lysates and in conditioned media (data not shown). Thus, a portion of Notch1 decoy is soluble in the extracellular environment.

Western blotting. Ad encoding Notch1 (Ad-Notch1) decoy-transduced HUVEC were cultured in endothelium serum-free medium (Life Technologies-Invitrogen) at 48 h and Mm5MT-FGF4 transfectants in DMEM. Western blots were performed using anti-human Fc (Pierce).

Quantitative reverse transcription-PCR. Mm5MT transfectants were cultured 7 d with vehicle or 1 μ mol/L PD166866 [inhibitor of FGF receptor (FGFR) kinase], total RNA isolated (RNeasy mini-kit, Qiagen), and first-strand cDNA synthesized (SuperScript First-Strand Synthesis System, Invitrogen). Quantitative reverse transcription-PCR (RT-PCR) for β -actin, FGF4, Hey1, VE-Cadherin, Jagged1, Dll1, and Dll4 (SYBR Green PCR Master Mix, 7300 Real-Time PCR; Applied Biosystems) was performed in triplicate, and values were normalized for β -actin. Values are shown for fold induction compared with controls (primer sequences available on request).

Coculture signaling assay. Notch1 decoy inhibition of ligand-induced signaling was performed as described (15). HeLa cells were transfected with 333 ng pBos-Notch1, 333 ng pGA981-6 (19), and 83 ng pLNC-LacZ with either 666 ng pCMV-Fc or pHyTC-Notch1 decoy (333 ng for 1 $\times$, 666 ng for 2 $\times$). 293 cells were transfected with 680 ng pHyTC-Jagged1, pHyTC-Dll1, pHyTC-Dll4, or pHyTC-X (empty vector). Cells were harvested, luciferase activity was determined 48 h posttransfection (enhanced luciferase assay kit, BD Pharmingen), and β -galactosidase activity was determined (Galacto-Light Plus kit, Applied Biosystems). Assays were performed in triplicate.

Endothelial coculture morphogenesis assay. HUVEC morphogenesis was assessed as described (15), modified by adding coculturing of Ad-Notch4-transduced HUVEC with Notch1 decoy-HUVEC or Fc-HUVEC transfectants. Ad-GFP at 10 m.o.i. was cotransduced in HUVECs with Ad-LacZ or Ad-Notch4 at 30 m.o.i. and, 48 h later, seeded on fibrin gels (24-well plates, 1.5×10^4 cells per well). Stable HUVEC-mock (HUVEC-X), HUVEC-Fc, or HUVEC-Notch1 decoy transfectants were seeded at 1.35×10^5 cells per well, and vehicle or 200 nmol/L compound E added 3 h later. Seven days later, HUVEC morphogenesis was calculated as the number of GFP-positive cells with processes compared with total GFP-positive cells per field.

Mouse dorsal air sac assay. The dorsal air sac (DAS) angiogenesis assay was performed as described (20) with minor changes. Millipore chambers were packed with 5.0×10^6 KP1/VEGF cells transduced (60 m.o.i.) with either Ad-GFP or Ad-Notch1 decoy and transplanted into the DAS of C57BL/6 mice ($n = 3-5$ each, with experiments performed in triplicate). Photographs were taken 4 d after implantation. To control for the effects of Notch1 decoy on growth of KP1 cells in culture (data not shown).

Colony formation (Clonogenic) assay. 0.66% agar (250 μ L; Agra noble, Difco) in DMEM (agar solution) was added into 24-well plates. After agar became solid, 250 μ L of 1:1 mixture of agar solution and cell suspension were overlaid at 1.5×10^3 cells per well and kept at 4°C for 30 min and then 250 μ L of agar solution was added again. DMEM (750 μ L) was aliquoted into well and changed twice a week for 2 wk. Cell numbers were measured using the Cell Counting Kit-8 (Dojindo Molecular Technologies). Data was shown as percentage of control compared with mock transfectants (Mm5MT-FGF4-X).

Mm5MT tumor model. Female C3H mice (6-8 wk old; Taconic) underwent s.c. implantation of 10^6 Mm5MT transfectants ($n = 10$ each). Tumor diameters were measured with calipers, and volume was calculated [$\text{length (mm)} \times \text{width (mm)}^2 \times \frac{1}{2}$]. Tumors were harvested at day 22 and analyzed. Experiments were performed thrice.

Immunohistochemistry. Fresh-frozen Mm5MT tissue sections (5 μ m) were immunostained (see supplementary data for antibody list; ref. 21). CD31 quantitation was performed using an Eclipse E800 microscope and ImagePro Plus v.4.01. Twenty different fields per slide were measured, and density ratios were calculated as (area of specific staining)/(total area, each field). Data are shown as the ratio of the mean of average density ratios of each Mm5MT transfectant to Mm5MT mock-transfectant.

NGP tumor model. The NGP tumor model has previously been described in detail (22). NGP cells were transfected with LacZ or Notch1

decoy, as above, and 10^6 NGP-LacZ or NGP-Notch1 decoy cells implanted intrarenally in 4-wk-old to 6-wk-old NCR nude mice (Taconic; NGP-LacZ $n = 11$, NGP-Notch1 decoy $n = 13$). At 6 wk, tumors were harvested for analysis. Paraffin-embedded sections ($5 \mu\text{mol/L}$) were immunostained for CD-31/PECAM and α -smooth muscle actin (αSMA). To detect apoptosis [terminal transferase deoxyuridine nick end labeling (TUNEL) assay], we used the Apoptag Red *in situ* kit (Chemicon). Signal was quantified by photographing 20 to 23 randomly selected fields of each tissue, excluding areas of normal kidney. Each frame was photographed in both red (TUNEL signal) and green channels. Using Adobe Photoshop, green channel signals were subtracted to eliminate erythrocyte autofluorescence. A uniform red-channel threshold was arbitrarily selected, and total signal area was measured in four NGP-Notch1 decoy and three NGP-LacZ tumors. Erythrocyte quantification was performed similarly.

Statistical analysis. Significance in quantitative studies was assessed using Tukey-Kramer tests (CD31 quantitation) and Kruskal-Wallis analysis (all others).

Results

Notch1 decoy inhibits ligand-induced Notch signaling in cells expressing Notch1. Notch1 decoy is based on the ectodomain of rat Notch1 fused to human IgG Fc (Fig. 1A) and is secreted, as determined by blotting of conditioned media from Ad-Notch1 decoy-infected HUVEC (Fig. 1B). We assessed Notch1 decoy activity using coculture signaling assays (15). 293 cells expressing Notch ligands, Jagged1, Dll1, or Dll4 activated Notch signaling when cultured with HeLa cells expressing Notch1, as measured by CSL-luciferase reporter activity (Fig. 1C). Expression of Notch1 decoy in either HeLa (Fig. 1C) or 293 cells (data not shown) blocked Notch1 signaling in coculture assays, indicating that this construct prevented Notch1 activation by Jagged1, Dll1, or Dll4 and, thus, is likely to function as a pan-ligand inhibitor of Notch1 signaling.

F1




Figure 2. Notch1 decoy or compound E blocks Notch4-mediated HUVEC extensions. **A**, ectopic expression of Notch4 induces morphogenetic changes by HUVECs cultured on fibrin gel. HUVECs were transduced with Ad-Notch4 at 30 m.o.i. and Ad-GFP at 10 m.o.i. to mark-infected cells. Two days later, HUVEC transfectants were cocultured with transduced HUVECs on fibrin gel and morphologic changes were documented using fluorescence microscopy. Notch4-induced cell extensions (right, white arrows). **B**, notch inhibition blocks Notch4-mediated HUVEC extensions. Notch4 expression induced cell extensions (top center) compared with control LacZ expressing HUVEC (top left), whereas treatment with 200 nmol/L compound E blocked Notch4-induced extensions (top right). Notch1 decoy expression blocks Notch4-induced cell extensions. Adenovirus-transduced HUVECs were cocultured on fibrin gels with stable HUVEC transfectants expressing either Fc (bottom left) or Notch1 decoy (bottom right) and photographed 2 d later. Bar, 200 μm . **C**, quantification of effect of Notch signal inhibition on Notch4-induced extensions. Reduction in extensions was statistically significant after treatment with compound E and expression of Notch1 decoy ($P < 0.0001$, both). Columns, mean; bars, SD.




Figure 3. Role of Notch signaling in VEGF-dependent *in vivo* angiogenesis. Inhibition of KP1/VEGF-induced angiogenesis with Notch1 decoy in mouse DAS assay. Representative photographs. *Top*, subcutaneous VEGF-induced angiogenesis with control COL1 (left) and KP1/VEGF cells transduced with GFP (middle) or with Notch1 decoy (right). *Bottom*, immunohistochemical analysis with CD31/PECAM antibody in muscle layer of skin (20 $\times$).

F2

Notch1 decoy blocked morphogenesis of HUVEC induced by Notch4. HUVECs transduced with Notch4 formed cellular extensions when cocultured with control HUVECs on fibrin gels (Fig. 2A), resembling morphologic changes induced by VEGF and FGF2 (23, 24). Using a CSL-Notch reporter introduced into HUVEC, we found that ectopic Notch4 expression in HUVEC or ectopic Notch4/Dll4 coexpression can increase Notch signaling over basal signaling (Supplementary Fig. S1). Previous reports have shown that growth of ECs on fibrin induced Jagged1 expression, therefore, it is highly likely that Jagged1 was expressed in HUVECs grown on fibrin (25). In our assay, endogenous Notch ligands expressed by HUVECs may activate the exogenous Notch4 to promote formation of cellular extensions. We examined this possibility using either compound E, a γ -secretase inhibitor (GSI), or Notch1 decoy. Compared with vehicle, treatment with 200 nmol/L compound E clearly inhibited extensions in Notch4-HUVECs (Fig. 2B, *top* and Fig. 2C). Coculturing of Ad-Notch4 transduced HUVECs with Notch1 decoy-HUVEC transfectants similarly blocked endothelial extensions relative to Fc-HUVEC transfectants (Fig. 2B, *bottom* and Fig. 2C). Reduction in formation of cellular extensions was significant (Fig. 1D; $P < 0.0001$ for both compound E treatment and Notch1 decoy transduction; data shown as mean $\pm$ SD).

Collectively, these data indicate that Notch receptor activation seems to be involved and in part required to induce HUVEC extensions in this assay and that the Notch1 decoy functions similarly to GSI, further validating its activity as an inhibitor of multiple Notch ligand-receptor interactions.

The Notch1 decoy inhibits VEGF-induced angiogenesis in murine dermis. The role of Notch in physiologic angiogenesis was evaluated using a DAS assay (26), in which a chamber containing VEGF-A¹²¹-expressing pancreatic KP1 tumor cells KP1 (KP1/VEGF¹²¹) is implanted under the dorsal skin of a mouse. Angiogenesis was induced in the dermal smooth muscle layer overlying the KP1/VEGF¹²¹ chamber (Fig. 3) but was significantly inhibited when KP1/VEGF¹²¹ cells also expressed Notch1 decoy (Fig. 3, *top*), as evidenced by immunostaining for the endothelial marker CD31/PECAM (Fig. 3, *bottom*). KP1/VEGF¹²¹ and Ad-GFP-infected KP1/VEGF¹²¹ cells elicit a similar angiogenic response (data not shown). These data suggest that dermal angiogenesis induced by VEGF requires Notch receptor activation. In this model, the Notch1 decoy is secreted from the cells in the implanted chamber and acts on vessels in adjacent tissue by diffusing out of

the chamber as a soluble agent. To detect secreted Notch1 decoy, we immunostained for human Fc and found this deposited perivascularly and diffusely in tissues external to the implanted chamber (Supplementary Fig. S2).

FGF4 induced the expression of Notch ligands, Jagged1, and Dll1, in mouse mammary tumor Mm5MT cells. Overexpression of FGF4 in Mm5MT cells promoted tumorigenicity in clonogenic and xenograft assays (data not shown). Because the tyrosine kinase pathway involving HGF/mitogen-activated protein kinase signaling induced Jagged1 expression in HNSCC (10), we asked whether FGF4, via stimulation of tyrosine kinase signaling, would stimulate analogous expression of Notch ligands in Mm5MT cells. We detected up-regulation of Jagged1 and Dll1 in Mm5MT-FGF4 transfectants using quantitative PCR (Dll4 expression was unaltered; Fig. 4A). Immunoblotting confirmed up-regulation of Jagged1 protein in Mm5MT-FGF4 cells compared with control Mm5MT cells (Fig. 4B). The FGFR kinase inhibitor PD166866 (14) suppressed induction of both Jagged1 and Dll1 in Mm5MT-FGF4 transfectants (Fig. 4C), indicating that FGF4-induced Jagged1 and Dll1 expression requires FGFR signaling. We also evaluated the expression of several known angiogenic factors by quantitative RT-PCR, comparing Mm5MT-FGF4 cells to Mm5MT-FGF4 cells expressing Notch1 decoy. No major difference in the expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D, placental growth factor, FGF1, FGF2, FGF4, platelet-derived growth factor-B, or angiopoietin 4 were detected when Mm5MT-FGF4 or Mm5MT-FGF4-Fc cells were compared with Mm5MT-FGF4 cells expressing Notch1 decoy (Supplementary Fig. S3A).

Notch1 decoy expression inhibited angiogenesis and growth of Mm5MT-FGF4 tumors in mice. Tumorigenicity of Mm5MT-FGF4 expressing Notch1 decoy was unaltered compared with Mm5MT-FGF4 cells or Mm5MT-FGF4 cells stably overexpressing Fc, as evaluated by a clonogenic assay *in vitro* (Fig. 5A). We hypothesized that Mm5MT-FGF4 tumors expressing Jagged1 would promote angiogenesis by signaling via endothelial Notch receptors. Thus, we evaluated the effect of Notch1 decoy expression on Mm5MT-FGF4 xenograft growth after s.c. implantation in mice. Immunostaining confirmed strikingly increased Jagged1 in Mm5MT-FGF4 tumors (Fig. 4D). In addition, Notch4 was detected in Mm5MT-FGF4 tumor endothelium (data not shown). Mm5MT-FGF4-Notch1 decoy xenograft growth was significantly delayed compared with both Mm5MT-FGF4 mock

F3

F4

F5


and Fc transfectants, suggesting that Notch inhibition had impaired a critical element in tumorigenesis (Fig. 5B). Immunostaining for CD31/PECAM showed marked inhibition of angiogenesis in Mm5MT-FGF4-Notch1 decoy tumors (Fig. 5C). Consistent with a requirement for Notch in vessel assembly, ECs appeared as detached solitary cells or small clusters, with few organized vessels detected. Quantitative analysis of anti-CD31 staining showed a 58% decrease in microvessel density in Notch1 decoy-expressing tumors ($P < 0.001$ for both Mm5MT-FGF4-X and Mm5MT-FGF4-Fc versus Mm5MT-FGF4-Notch1 decoy; data shown as mean $\pm$ SD; Fig. 5D). Consistent with the immunohistochemical data, quantitative RT-PCR analyses of pooled tumor RNA revealed a 60% reduction in VE-Cadherin expression in the Mm5MT-FGF4-Notch1 decoy tumors compared with the Fc control tumors (Supplementary Fig. S3B). Expression of Hey1, a direct target of Notch/CSL signaling in ECs, was decreased 2.7-fold in the Notch1 decoy-expressing tumors compared with controls (Supplementary Fig. S3C). Taken together, these data indicate that Notch1 decoy expression inhibited Notch signaling in tumors concurrent with a quantitative decrease in vasculature.

The effects of Notch1 decoy on Mm5MT-FGF4 tumor angiogenesis we observed differed from previous reports of inhibition of the Notch ligand Dll4 in tumor xenografts, in which growth was restricted concurrent with overgrowth of a dysfunctional tumor vessel network (8, 9). Therefore, to determine whether an overgrowth phase occurred in our system, we evaluated tumor vasculature at an earlier time point during Mm5MT-FGF4 tumor growth. The first evidence of reduction in Mm5MT-FGF4-Notch1 decoy tumor growth (compared with Mm5MT-FGF4-X or Mm5MT-FGF4-Fc controls) is detectable at day 12. We quantitated tumor endothelium at this time point (day 12) but found no significant difference in PECAM-positive endothelium and no significant difference in the appearance of

Dll4-positive tumor vessels when comparing control to Notch1 decoy-expressing tumors (Supplementary Fig. S4). We examined apoptosis in Mm5MT-FGF4-Notch1 decoy tumors compared with Mm5MT-FGF4-X and Mm5MT-FGF4-Fc controls at both time points by TUNEL assay but no significant difference was identified (data not shown).

Notch1 decoy expression disrupted angiogenesis in human NGP neuroblastoma xenografts. NGP xenografts in mice form a mature hierarchical vasculature that is comparatively resistant to VEGF blockade (22). To determine whether Notch receptor activation contributed to NGP angiogenesis, we transfected NGP cells with Notch1 decoy, as above. To confirm the presence of Notch1 decoy, we immunostained tumor sections using antihuman Fc antibodies and detected signal both around the tumor cells and perivascularly (data not shown). Thus, Notch1 decoy may interact with multiple different cell types in tumor xenografts. Similar to results observed with Mm5MT-FGF4-Notch1 decoy cells, neither NGP cell proliferation in culture nor colony formation in soft agar was affected by expression of the Notch1 decoy (data not shown). However, xenograft viability was strikingly impaired (Fig. 6A), with significantly increased tumor cell apoptosis ($P = 0.0002$; TUNEL-positive cells in NGP-Notch1 decoy versus NGP-LacZ tumors; Fig. 6B). Intratumoral hemorrhage was significantly increased in NGP-Notch1 decoy tumors, suggesting that vessels were physically disrupted ($P < 0.0001$; Fig. 6C). Immunostaining for the vascular basement membrane component, collagen IV indicated an overall decrease in vasculature, with diminished branching, although remaining collagen sleeves seemed smooth and intact (not shown). However, immunostaining for ECs and vascular mural cells (VMC; using anti-CD31 and anti- α SMA antibodies, respectively) showed disorder of these normally contiguous cell layers. Individual vascular cells seemed irregular and were erratically detached from one another, with loss of vessel continuity (Fig. 6D). NGP tumor cells did not express Jagged-1, although immunostaining showed

Figure 4. FGF4 induces the expression of Notch ligands in murine mammary carcinoma Mm5MT cells. Stable Mm5MT transfectants generated by retroviral gene transfer. A, quantitative RT-PCR analysis of the expression of Notch ligands showing induction of Jagged1 and Dll1 in Mm5MT-FGF4 compared with mock transfectants (Mm5MT-X). *, $P < 0.05$. B, Jagged1 protein is elevated in Mm5MT-FGF4 versus Mm5MT-X, as determined by Western blotting. C, reduction of Notch ligand expression in Mm5MT-FGF4 cells with PD166866, an inhibitor of FGFR kinase. *, $P < 0.05$. D, immunohistochemical analysis of Jagged1 staining in Mm5MT transfectants. Bar, 50 μ m.






Figure 5. Notch1 decoy inhibits angiogenesis and s.c. tumor growth of Mm5MT-FGF4 tumors in mice. **A**, Mm5MT-FGF4 tumor growth in soft agar is little affected by expression of Fc or N1 decoy. **B**, tumor volumes of Mm5MT-FGF4-X and Mm5MT-FGF4-Fc differ significantly from Mm5MT-FGF4-Notch1 decoy transfectants in mice (**, day 21, $P = 0.037$ and $P = 0.008$, Mm5MT-FGF4-X and Mm5MT-FGF4-Fc versus Mm5MT-FGF4-Notch1 decoy, respectively). Points, mean; bars, SD. **C**, immunohistochemical analysis of neovessels with CD31/PECAM staining within day 21 tumors derived from Mm5MT-FGF4 transfectants. Top, bar, 100 μm; bottom, bar, 50 μm. **D**, quantitative analysis showed a reduction in CD31(+) neovessels in Mm5MT-FGF4-Notch1 decoy transfectants compared with Fc or mock-transfected tumors (*, $P < 0.001$ for both Mm5MT-FGF4-X and Mm5MT-FGF4-Fc versus Mm5MT-FGF4-Notch1 decoy). Columns, mean; bars, SD.

expression in vasculature (data not shown). Taken together, these results suggest that Notch1 decoy expression disrupted Notch-mediated endothelial and VMC interactions in tumor vasculature, leading to instability, hemorrhage, and defective perfusion of tumor tissues.

Discussion

Recent reports confirm the critical role of the Notch ligand Dll4 in angiogenesis and show that Dll4 blockade can effectively repress tumor growth by deregulating vascular development (8, 9). In this study, we show that blockade of Notch receptor function using a novel secreted construct derived from the Notch1 ectodomain effectively inhibits angiogenesis. The Notch1 decoy inhibited ligand-dependent Notch1 signal activation induced by ligands Jagged1, Dll1, and Dll4. Thus, Notch1 decoy likely acts to block multiple distinct ligand receptor combinations that participate in physiologic or pathologic angiogenesis. Consistent with a role for Notch receptor activation in neoangiogenesis, overexpression of Notch4-induced EC extensions, which could be prevented by blocking

Notch signaling with either Notch1 decoy or GSI. Similarly, diffusion of Notch1 decoy from an implanted chamber reduced VEGF-stimulated angiogenesis in the dermis. Although Notch1 decoy did not inhibit tumor cell growth *in vitro*, expression of Notch1 decoy inhibited growth and angiogenesis of Mm5MT-FGF4 xenografts, in which Jagged1 expression is up-regulated. Similarly, Notch1 decoy expression had no effect on NGP tumor cell proliferation *in vitro* but disrupted tumor vessels and viability *in vivo*.

Overall, the effects of Notch1 decoy on dermal and tumor angiogenesis in these studies are distinct from those previously reported for Dll4 blockade in tumors. Most notable among these differences is the lack of observable overgrowth of endothelium in response to Notch1 decoy expression observed in all three of the *in vivo* angiogenesis models we used. In the Mm5MT-FGF4 model, evaluation of both early (day 12) and later (day 21) time points for tumor evaluation showed either equivalent (day 12) or reduced (day 21) EC content. Similarly, in the NGP tumor model, Notch1 decoy expression resulted in vascular disruption, without evidence of overgrowth. It is thus clear that response to Notch1

decoy expression is unique, likely reflecting the interruption of multiple Notch ligand–receptor interactions acting on endothelium as opposed to the effects observed after the selective inhibition of Dll4.

Notch4 overexpression in HUVECs was sufficient to induce endothelial extensions on fibrin gel without exogenous expression of Notch ligands (Fig. 2). Because fibrin is known to induce Jagged1 expression in EC and, thus, may have functioned to promote HUVEC expression of Jagged1 in this assay, we speculate that this caused activation of Notch4; in reporter assays, increased Notch activity was found when HUVECs engineered to express Dll4 and Notch4 were cocultured, suggesting that paracrine signaling is responsible for enhanced Notch signaling. In HeLa coculture signaling assays, the Notch1

decoy inhibited signaling via ligand–Notch1 receptor interaction. We were unable to similarly evaluate Notch4 activity, as Notch4 was poorly processed and presented on the surface of HeLa cells (data not shown). However, processed Notch4 is found on HUVECs after adenoviral Notch4 transduction (not shown), indicating that Notch1 decoy can block ligand-induced Notch4 activation (27).

Expression of the Notch1 decoy also blocked new vessel growth stimulated by VEGF¹²¹ in the dermis, consistent with previous work demonstrating that Notch receptor activation is required for VEGF-induced up-regulation of target genes (28). One of these endothelial target genes is Dll4, which acts to reduce VEGFR2 and neuropilin-1 expression in a negative feedback loop (12). As above, inhibition of Dll4 disrupts this loop and results in deregulated




Figure 6. Notch1 decoy expression disrupts angiogenesis and impairs tumor viability in human NGP xenografts. We have previously reported that human neuroblastoma xenografts in mice have a mature, hierarchical vasculature that is relatively resistant to VEGF blockade (22). To determine whether Notch receptor activation contributed to NGP angiogenesis, we transfected NGP cells with the Notch1 decoy construct, which did not affect their ability to grow in culture (data not shown). There was, however, a marked decrease in tumor viability *in vivo* (A; red fluorescence, TUNEL; green fluorescence, erythrocytes; bar, 100 μ m), with significantly increased fields that had high levels of tumor cell apoptosis [B; $P = 0.0002$; TUNEL-positive cells in NGP–Notch1 decoy (■) versus NGP–LacZ (■) tumors], and increased intratumoral hemorrhage [C; *, $P < 0.0001$, quantitation of parenchymal erythrocyte signal, NGP–Notch1 decoy (■) versus NGP–LacZ (■) tumors]. In addition, the tumor vessel networks in NGP–Notch1 decoy xenografts seemed to have been physically disrupted compared with NGP–LacZ controls, with immunostaining for ECs and VMCs (using anti-CD31/PECAM and α SMA antibodies, respectively) demonstrating lack of continuity of these vascular cell layers (D; bar, 50 μ m). Individual vascular cells seemed detached from one another. Taken together, these results suggest that Notch1 decoy expression disrupted the ability of ECs and VMCs to form stable vascular conduits, causing vessel breakdown, hemorrhage, and ischemia of tumor tissues.

sprouting, forming a nonfunctional vasculature (8, 9). However, Notch1 decoy expression exerts a different effect, repressing neoangiogenesis, potentially reflecting disruption of other Notch ligand: receptor interactions (e.g., Jagged1/Notch1, as discussed below). Taken together, these data suggest a model in which construction of a vessel network is exquisitely regulated by cross-talk between Notch and VEGF pathways at multiple points, with different Notch receptor and ligand pairs playing distinct roles in this process.

The multiple roles recently shown for Notch signaling in tumorigenesis increase the attractiveness of this pathway as a potential target for cancer therapy. Whereas Notch activation is likely to function directly in malignant transformation in human cancers (29, 30), it seems to be required for angiogenesis in a number of tumor systems (8, 9) and in our models presented here. Interestingly, Notch ligand induction can be regulated by growth factor signals. For example, Jagged1 is induced in tumor cells by HGF (10) and Dll4 induced in ECs by VEGF (11). Here, we show that FGF4 can similarly stimulate Jagged1 and Dll1 expression in murine Mm5MT cells. Notch1 decoy reduced Mm5MT-FGF4 tumor growth and angiogenesis *in vivo* but did not affect tumorigenicity *in vitro*. Similarly, expression of Notch1 decoy did not affect NGP tumor growth *in vitro* while strikingly disrupting NGP vasculature *in vivo*. Thus, these results suggest that Notch receptor activation in Mm5MT and NGP vessels rather than tumor cells is required for neoplastic growth in these neoplasms.

While both Mm5MT-FGF4 and NGP xenografts displayed striking disorder of tumor vasculature after Notch1 decoy expression, the differences in vascular phenotype observed in these models suggest that tumor-specific patterns of Notch ligand/receptor interaction may fine-tune vessel assembly. Mm5MT-FGF4 tumors strongly express Jagged-1, proliferate rapidly, and develop dense, erratic endothelial networks relatively devoid of recruited VMCs. Consistent with previous data indicating that tumor cell expression of Jagged-1 can stimulate Notch-dependent angiogenesis (10), Notch1 decoy expression caused profound ablation of Mm5MT-FGF4 vasculature by day 21, leaving small clusters or individual ECs isolated in tumor parenchyma. In contrast, NGP tumors developed a mature vascular plexus, with near-uniform

coverage of endothelium by VMCs. Also in contrast to the Mm5MT-FGF4 model, NGP vessels strongly expressed Jagged-1, whereas NGP tumor cells did not. Notch1 decoy expression in NGP tumors causes intratumoral hemorrhage and necrosis, with loss of vessel continuity. We speculate that the strikingly different patterns of Jagged-1 expression in the Mm5MT-FGF4 and NGP models (tumor cell versus EC) may contribute to the distinct effects of the Notch1 decoy in each. For example, engagement of Jagged-1 expressed by Mm5MT-FGF4 tumor cells by endothelial Notch receptors may be required for new tumor vessels to sprout. Notch1 decoy expression disrupted this interaction and limited new tumor growth. In contrast, NGP vessels may be stabilized by Notch-mediated signaling between adjacent vascular cells, so that Notch1 decoy caused discontinuity in already-formed vessels with loss of tumor perfusion.

Collectively, these data provide support for a model in which Notch signaling controls interactions between the multiple cell types responsible for tumor angiogenesis. Whereas Notch activation is broadly required for new vessel formation, tumor and vascular cell expression of individual Notch proteins may differentially regulate vascular sprouting and remodeling. Our results confirm the importance of Notch ligand receptor interactions in tumor vasculature and suggest that perturbing Notch receptor function may provide a novel and effective means of disrupting tumor angiogenesis.

Disclosure of Potential Conflicts of Interest

The authors declare that they have no competing financial interest in this work.

Q4

Acknowledgments

Received 12/7/2007; revised 4/10/2008; accepted 4/11/2008.

Grant support: NIH grants 5R01HL62454 (J.K. Kitajewski), 5R01CA100451 (J.J. Kandel), R01CA088951 (D.J. Yamashiro), K08CA107077 (J. Huang), and 5K01DK744629 (C.J. Shawber); Department of Defense grant W81XWH-07-1-0362 (J.K. Kitajewski); Children's Neuroblastoma Cancer Foundation (S. Huang, D.J. Yamashiro); and Taysandz, Inc. (D.J. Yamashiro).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We dedicate this work to the memory of Dr. Judah Folkman.

References

- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004;25: 581-611.
- Jain R, Duda D, Clark J, Loeffler J. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 2006;3:24-40.
- Kopan R. Notch: a membrane-bound transcription factor. *J Cell Sci* 2002;115:1095-7.
- Shawber C, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. *Bioessays* 2004;26:225-34.
- Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of δ -like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc Natl Acad Sci U S A* 2004;101:15949-54.
- Patel NS, Li J-L, Generali D, Poulson R, Cranston DW, Harris AL. Up-regulation of Delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. *Cancer Res* 2005;65:8690-7.
- Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial Delta-like 4 expression correlates with vessel maturation in bladder cancer. *Clin Cancer Res* 2006;12:4836-44.
- Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. *Nature* 2006;444:1083-7.
- Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. *Nature* 2006;444: 1032-7.
- Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. *Cancer Cell* 2005;8:13-23.
- Liu Z-J, Shirakawa T, Li Y, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. *Mol Cell Biol* 2003;23: 14-25.
- Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. *Blood* 2006;107: 931-9.
- Shawber CJ, Funahashi Y, Francisco E, et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. *J Clin Invest* 2007;117:3369-82.
- Panek RL, Lu GH, Dahring TK, et al. *In vitro* biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. *J Pharmacol Exp Ther* 1998; 286:569-77.
- Das I, Craig C, Funahashi Y, et al. Notch oncoproteins depend on γ -secretase/presenilin activity for processing and function. *J Biol Chem* 2004;279:30771-80.
- Shawber CJ, Das I, Francisco E, Kitajewski JAN. Notch signaling in primary endothelial cells. *Ann NY Acad Sci* 2003;995:162-70.
- Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. *J Virol* 1997;71:1842-9.
- Jaffe E, Nachman R, Becker C, Minick C. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. *J Clin Invest* 1973;52:2745-56.
- Kato H, Sakai T, Tamura K, et al. Functional conservation of mouse Notch receptor family members. *FEBS Lett* 1996;395:221-4.
- Funahashi Y, Wakabayashi T, Semba T, Sonoda J, Kitoh K, Yoshimatsu K. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. *Oncol Res* 1999; 11:319-29.

21. Vorontchikhina MA, Zimmermann RC, Shawber CJ, Tang H, Kitajewski J. Unique patterns of Notch1, Notch4 and Jagged1 expression in ovarian vessels during folliculogenesis and corpus luteum formation. *Gene Expr Patterns* 2005;5:701–9.
22. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. *Proc Natl Acad Sci U S A* 2002; 99:11399–404.
23. Montesano RLO. Phorbol esters induce angiogenesis *in vitro* from large-vessel endothelial cells. *J Cell Physiol* 1987;130:284–91.
24. Koolwijk P, van Erck MG, de Vree WJ, et al. Cooperative effect of TNF α , bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. *J Cell Biol* 1996;132:1177–88.
25. Zimrin AB, Pepper MS, McMahon GA, Nguyen F, Montesano R, Maciag T. An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis *In vitro*. *J Biol Chem* 1996; 271:32499–502.
26. Funahashi Y, Wakabayashi T, Semba T, Sonoda J, Kitoh KKY. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. *Oncol Res* 1999;11: 319–29.
27. Shawber CJ, Das I, Francisco E, Kitajewski J. Notch signaling in primary endothelial cells. *Ann N Y Acad Sci* 2003;995:162–70.
28. Hainaud P, Contreres JO, Villemain A, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. *Cancer Res* 2006;66:8501–10.
29. Nickoloff B, Osborne B, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. *Oncogene* 2003;22:6598–608.
30. Radtke F, Raj K. The role of notch in tumorigenesis: oncogene or tumour suppressor? *Nat Rev Cancer* 2003;3: 756–67.

Q3